Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Maarouf, Adil, Rico, Audrey, Boutiere, Clemence, Perriguey, Marine, Demortiere, Sarah, Pelletier, Jean, Audoin, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357416/
https://www.ncbi.nlm.nih.gov/pubmed/32587103
http://dx.doi.org/10.1212/NXI.0000000000000825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357416/
https://www.ncbi.nlm.nih.gov/pubmed/32587103
http://dx.doi.org/10.1212/NXI.0000000000000825

Ejemplares similares